 Introducing the open innovation model in Polish biopharmaceutical companies: major drivers and barriersMałgorzata Runiewicz-Wardyn and Joanna Lesniowska Ekonomista, 2023, issue 1, 51-77 Abstract: Innovation is one of the most critical determinants of economic success and one of the most important elements in building a competitive advantage. The COVID-19 pandemic has led to the development of new strategic partnerships, including open innovation alliances, in the biopharmaceutical industry. The adoption of open innovation strategies has been a persistent trend, although these strategies vary onsiderably from one country to another. The lowest level of open cooperation and R&D collaboration in the biopharmaceutical industry can be observed in Central and Eastern Europe, including Poland. The main barriers to, and challenges facing, open innovation cooperation in the Polish biopharmaceutical sector, however, are not well understood. This study analyses the major drivers of, and barriers to, engaging in open innovation cooperation. A survey was conducted and established that open innovation cooperation and R&D collaboration do not necessarily suffer from a lack of financial resources, but are definitely dependent on such socio-behavioural factors as motivation for collaboration, value systems, and trust between partners. Keywords: development; biopharmaceutical industry; open innovation strategies (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:aoq:ekonom:y:2023:i:1:p:51-77 Access Statistics for this article More articles in Ekonomista from Polskie Towarzystwo Ekonomiczne Contact information at EDIRC. |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.